SRPT News and Press, Sarepta Therapeutics Inc. From 05/20/24

2024-05-20 13:58:20 ET Summary PepGen's stock has experienced extreme volatility, with an 80% drop, a 370% rebound, and subsequent decline in 14 months. The rebound was driven by news that Sarepta's DMD exon 51 candidate had lower skipping output than PepGen's PGN-EDO51. PepGe...

2024-05-20 09:58:45 ET More on PTC Therapeutics PTC Therapeutics: Multiple Regulatory Submissions Along With Data Cuts PTC Therapeutics, Inc. (PTCT) Q1 2024 Earnings Call Transcript PTC Therapeutics, Inc. (PTCT) Q4 2023 Earnings Call Transcript PTC Therapeuti...

2024-05-14 09:00:16 ET More on Sarepta Therapeutics Sarepta Therapeutics, Inc. (SRPT) Q1 2024 Earnings Call Transcript Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy Sarepta Therapeutics: Another 'Hold' Call Ahead Of Some Key Catalysts HHS pa...

2024-05-09 18:44:45 ET More on Catalyst Pharmaceuticals, Sarepta Therapeutics, etc. Catalyst Pharmaceuticals, Inc. (CPRX) Q1 2024 Earnings Call Transcript Sarepta Therapeutics, Inc. (SRPT) Q1 2024 Earnings Call Transcript Sarepta Therapeutics: Growth Trajectory Alter...

2024-05-07 22:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-07 16:16:50 ET More on Pfizer, Sarepta Pfizer: Solid Earnings, But We're Not Out Of The Woods Yet Pfizer: Ignore The Dead Cat Bounce Pfizer Stock: Finally The Market Is Waking Up Pfizer hires Citi healthcare analyst Baum to lead strategy and innovatio...

2024-05-04 12:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotechnology offers breakthrough drugs and treatments that open new doors in the field of medicine. Companies are releasing more drugs and developing state-of-the-art methods to treat previous...

– TIME recognizes Dr. Mendell’s decades-long contributions in the treatment of neuromuscular disease and the advancement of gene therapy, including the first gene therapy for Duchenne muscular dystrophy Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precisio...

2024-05-02 15:36:47 ET More on Sarepta Therapeutics Sarepta Therapeutics, Inc. (SRPT) Q1 2024 Earnings Call Transcript Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy Sarepta Therapeutics: Another 'Hold' Call Ahead Of Some Key Catalysts Sarept...

2024-05-01 19:30:13 ET Image source: The Motley Fool. Sarepta Therapeutics (NASDAQ: SRPT) Q1 2024 Earnings Call May 01, 2024 , 4:30 p.m. ET Operator Continue reading For further details see: Sarepta Therapeutics (SRPT) Q1 2024 Earnings Call Tr...